WuXi Biologics (Cayman) Inc. (WXXWY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
WuXi Biologics (Cayman) Inc. (WXXWY) trades at $12.60 with AI Score 49/100 (Grade C). WuXi Biologics (Cayman) Inc. is a leading global contract development and manufacturing organization (CDMO) providing end-to-end solutions for biologics. Market cap: $25.9B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for WXXWY: WXXWY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WXXWY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
WXXWY: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
WuXi Biologics (Cayman) Inc. (WXXWY) Healthcare & Pipeline Overview
WuXi Biologics (Cayman) Inc. is a global CDMO specializing in biologics, offering comprehensive services from discovery to manufacturing. With a presence in China, North America, and Europe, the company supports pharmaceutical and biotech companies in developing innovative therapies, leveraging strategic partnerships and a broad service portfolio.
What Is the Investment Thesis for WXXWY?
WuXi Biologics presents a compelling investment case based on its strong market position in the rapidly growing biologics CDMO industry. The company's end-to-end service offerings, global presence, and strategic partnerships create a robust platform for sustained growth. With a current P/E ratio of 25.7 and a profit margin of 20.9%, WuXi Biologics demonstrates solid financial performance. Key growth catalysts include the increasing demand for biologics, expansion into new therapeutic areas, and continued penetration of international markets. However, investors may want to evaluate potential risks such as regulatory changes and competition within the CDMO space. The company's beta of 0.50 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
WXXWY Key Highlights
Market capitalization of $25.9B reflects strong investor confidence in WuXi Biologics' market position.
- P/E ratio of 25.7 indicates a premium valuation, reflecting expectations of future earnings growth.
- Profit margin of 20.9% demonstrates efficient operations and strong profitability.
- Gross margin of 42.7% highlights the company's ability to maintain competitive pricing and cost control.
- Beta of 0.50 suggests lower volatility compared to the broader market, potentially offering a more stable investment.
Who Are WXXWY's Competitors?
WXXWY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAG Adagene Inc. | $4.12 | +1.73% | $155M | 52 |
| BDRX Biodexa Pharmaceuticals Plc | $1.26 | +0.00% | 39 | |
| CORT Corcept Therapeutics Incorporated | $121.05 | +1.71% | $13.1B | 96 |
| EQRX EQRx, Inc. | $2.34 | -2.09% | $1.14B | — |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WXXWY's Key Strengths?
Comprehensive end-to-end service offerings.
- Global presence and established infrastructure.
- Strong track record and reputation.
- Strategic partnerships with leading pharmaceutical and biotech companies.
What Are WXXWY's Weaknesses?
Reliance on a limited number of large clients.
- Exposure to regulatory changes in China and other markets.
- Potential for increased competition in the CDMO space.
- Dependence on key personnel and expertise.
What Could Drive WXXWY Stock Higher?
Potential regulatory approvals for new biologics developed using WuXi Biologics' services.
- Increasing demand for biologics development and manufacturing services.
- Expansion into new therapeutic areas such as cell and gene therapy.
- Geographic expansion into underserved markets.
- Strategic acquisitions and partnerships to enhance service offerings.
What Are the Key Risks for WXXWY?
Economic downturns and reduced healthcare spending.
- Technological advancements that could disrupt the biologics market.
- Intellectual property disputes and patent challenges.
- Geopolitical risks and trade tensions.
- Reliance on a limited number of large clients.
What Are the Growth Opportunities for WXXWY?
- Expansion into New Therapeutic Areas: WuXi Biologics has the opportunity to expand its services into emerging therapeutic areas such as cell and gene therapy. By investing in specialized capabilities and expertise in these areas, WuXi Biologics can capture a significant share of this high-growth market. This expansion would diversify the company's revenue streams and reduce its reliance on traditional biologics.
- Geographic Expansion: WuXi Biologics can further expand its geographic footprint by establishing new facilities and partnerships in key markets such as Europe and North America. The global CDMO market is highly fragmented, with significant opportunities for consolidation and expansion. By increasing its presence in these regions, WuXi Biologics can better serve its global client base and capitalize on regional growth opportunities. This expansion would also mitigate the risk of over-reliance on any single geographic market.
- Strategic Partnerships and Acquisitions: WuXi Biologics can pursue strategic partnerships and acquisitions to enhance its service offerings and expand its market reach. By partnering with or acquiring companies with complementary capabilities, such as specialized formulation or analytical testing services, WuXi Biologics can strengthen its value proposition and attract new clients. These partnerships and acquisitions would also provide access to new technologies and expertise, further differentiating the company from its competitors.
- Increased Focus on Vaccine CDMO: With the growing demand for vaccines globally, WuXi Biologics can capitalize on the increasing need for vaccine development and manufacturing services. The global vaccine market is projected to reach $100 billion by 2027. By investing in specialized vaccine manufacturing capabilities and expertise, WuXi Biologics can secure a significant share of this market. This would diversify the company's revenue streams and contribute to global health security.
- Digital Transformation and Automation: WuXi Biologics can invest in digital transformation and automation technologies to improve its operational efficiency and reduce costs. By implementing advanced data analytics, artificial intelligence, and robotic process automation, the company can streamline its processes, improve quality control, and reduce lead times. This would enhance its competitiveness and improve its profitability. The adoption of digital technologies would also enable WuXi Biologics to offer new and innovative services to its clients.
What Are WXXWY's Competitive Advantages?
- End-to-end service offerings provide a comprehensive solution for clients, creating switching costs.
- Global presence allows the company to serve clients in multiple regions, expanding its market reach.
- Strategic partnerships enhance service offerings and market access.
- Strong track record and reputation for quality and reliability.
- Specialized expertise in biologics development and manufacturing.
What Does WXXWY Do?
Incorporated in 2014 and headquartered in Wuxi, China, WuXi Biologics (Cayman) Inc. has rapidly become a prominent player in the global biologics contract development and manufacturing organization (CDMO) space. The company provides end-to-end solutions, assisting clients from the initial stages of biologics discovery through development and large-scale manufacturing. WuXi Biologics operates in the People's Republic of China, North America, Europe, and other international markets. WuXi Biologics offers a comprehensive suite of services, including cell line development, process development, formulation, and manufacturing. These services cater to a diverse range of biologics, including monoclonal antibodies, bispecific antibodies, fusion proteins, and vaccines. The company's capabilities extend to both drug substance and drug product manufacturing, providing a seamless, integrated solution for its clients. Beyond its core CDMO services, WuXi Biologics also engages in consultation services related to biopharmaceutical technology, international sales contracting, testing technology development, sales and marketing, and biologics clinical and manufacturing services. They are also involved in the production and sale of medicals, vaccine CDMO, and material supplier activities. The company has established strategic partnerships with firms like ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc, enhancing its service offerings and market reach. WuXi Biologics' global presence and comprehensive service portfolio position it as a key partner for pharmaceutical and biotech companies seeking to develop and manufacture biologics.
What Products and Services Does WXXWY Offer?
- Provides end-to-end solutions for biologics discovery.
- Offers development services for biologics.
- Manufactures biologics for pharmaceutical and biotech companies.
- Provides consultation services in biopharmaceutical technology.
- Engages in international sales contracting services.
- Develops and tests testing technologies.
- Offers sales and marketing services for biologics.
- Provides biologics clinical and manufacturing services.
How Does WXXWY Make Money?
- Generates revenue through contract development and manufacturing services for biologics.
- Offers consultation services related to biopharmaceutical technology.
- Engages in international sales contracting services.
- Derives income from testing and development of testing technologies.
- Receives payments for sales and marketing services for biologics.
What Industry Does WXXWY Operate In?
WuXi Biologics operates within the rapidly expanding biologics CDMO industry. The increasing complexity and cost of biologics development have driven pharmaceutical and biotech companies to outsource these activities to specialized CDMOs. The global biologics market is projected to continue its strong growth trajectory, fueled by advancements in biotechnology and the rising prevalence of chronic diseases. Competition in the CDMO space is intensifying, with companies like WuXi Biologics vying for market share. WuXi Biologics differentiates itself through its comprehensive service offerings, global presence, and strong track record.
Who Are WXXWY's Key Customers?
- Pharmaceutical companies developing biologics.
- Biotech companies researching and developing new therapies.
- Academic institutions involved in biologics research.
- Government agencies involved in vaccine development and manufacturing.
- Other healthcare organizations seeking biologics development and manufacturing services.
WuXi Biologics (Cayman) Inc. (WXXWY) Valuation Context
Valued at $25.9B, WXXWY is classified as a large-cap stock. Relative to its peer group, WXXWY's quantitative score of 49/100 is below the peer average of 72/100.
WXXWY Revenue & Earnings Trend
In Q4 2025, WXXWY generated $11.62B in top-line revenue, marking a sequential increase of 16.7%. The company recorded net income of $2.52B, with diluted EPS of $1.18. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, WXXWY averaged $0.96 in diluted EPS.
Company Profile
WuXi Biologics (Cayman) Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wuxi, CN. The company is led by CEO Zhisheng Chen. WXXWY has traded publicly since 2017.
Key Financial Metrics
Return on equity for WuXi Biologics (Cayman) Inc. stands at 10.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.7%, showing how much profit it generates from its asset base. WXXWY trades at a trailing price-to-earnings ratio of 25.74, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
WuXi Biologics (Cayman) Inc.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 11.59 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
WuXi Biologics (Cayman) Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.6% above estimates on average.
Forward Outlook
Wall Street analysts project WuXi Biologics (Cayman) Inc. revenue of about $26.06B for fiscal 2026, with EPS near $2.61. The estimate reflects 23 contributing analysts.
WXXWY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's growth potential, indicating that leadership believes in upcoming developments.
- Community sentiment has shifted positively due to recent partnerships announced, which may enhance WuXi's service offerings and market reach.
- Analysts are optimistic about the biopharmaceutical sector's recovery, which could benefit WuXi as demand for biologics increases.
- The company's ongoing investments in R&D are seen as a strong commitment to innovation, positioning WuXi favorably in a competitive landscape.
Bear Case
- Concerns have arisen about regulatory pressures impacting the biopharmaceutical industry, creating uncertainty around operational stability.
- Recent community discussions reflect skepticism regarding the company's ability to scale rapidly amidst rising competition.
- Market perception has been affected by broader economic factors, leading to cautious sentiment around biotech investments.
- Some investors are wary of WuXi's reliance on partnerships, questioning whether these collaborations can deliver sustainable growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $11.62B | $2.52B | $1.18 |
| Q2 2025 | $9.95B | $2.34B | $1.10 |
| Q4 2024 | $10.10B | $1.86B | $0.86 |
| Q2 2024 | $8.57B | $1.50B | $0.70 |
Based on FMP financials and quantitative analysis
WXXWY Latest News
-
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
Yahoo! Finance: WXXWY News · Jul 9, 2026
-
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
Yahoo! Finance: WXXWY News · Jul 8, 2026
-
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
Yahoo! Finance: WXXWY News · Jun 30, 2026
-
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
prnewswire.com · Jun 24, 2026
WXXWY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WXXWY.
Price Targets
Wall Street price target analysis for WXXWY.
WXXWY MoonshotScore
What does this score mean?
The MoonshotScore rates WXXWY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
Leadership: Zhisheng Chen
CEO
Zhisheng Chen is the CEO of WuXi Biologics (Cayman) Inc. He has extensive experience in the biopharmaceutical industry. His background includes leadership roles in various multinational pharmaceutical companies. He is responsible for overseeing the company's overall strategy, operations, and financial performance. He manages a large workforce of 12,575 employees.
Track Record: Under Zhisheng Chen's leadership, WuXi Biologics has experienced significant growth and expansion. He has overseen the establishment of new facilities and the expansion of the company's service offerings. He has also played a key role in forging strategic partnerships with leading pharmaceutical and biotech companies. His leadership has contributed to the company's strong financial performance and market position.
WuXi Biologics (Cayman) Inc. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. WXXWY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the stringent listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to indirectly invest in WuXi Biologics.
- Home Market Ticker: Hong Kong Stock Exchange (WXXW)
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: WXXW
WXXWY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that WuXi Biologics (WXXWY) has limited regulatory oversight and disclosure requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet minimum financial standards or reporting requirements, increasing investment risk. Trading on the OTC Other tier can be less transparent and more volatile than trading on listed exchanges.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in WXXWY.
- Lower trading volume and wider bid-ask spreads can lead to price volatility and illiquidity.
- OTC stocks are subject to less regulatory oversight, increasing the potential for fraud or manipulation.
- The OTC Other tier carries a higher risk of company failure or delisting.
- Difficulty in obtaining reliable information about the company's operations and financial performance.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Strategic partnerships with reputable pharmaceutical companies.
- Global presence and established infrastructure.
- Strong track record in biologics development and manufacturing.
- Experienced management team with industry expertise.
- Positive media coverage and industry recognition.
What Investors Ask About WuXi Biologics (Cayman) Inc. (WXXWY) — Healthcare
What does the AI Score mean for WXXWY?
WXXWY holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. WuXi Biologics (Cayman) Inc. is a leading global contract development and manufacturing organization (CDMO) providing end-to-end solutions for biologics. The company supports the discovery …
What does WuXi Biologics (Cayman) Inc. do?
WuXi Biologics (Cayman) Inc. is a leading global contract development and manufacturing organization (CDMO) specializing in biologics. The company provides end-to-end solutions for pharmaceutical and biotech companies, assisting them from the initial stages of biologics discovery through development and large-scale manufacturing.
What do analysts say about WXXWY stock?
Analyst coverage of WXXWY stock is limited due to its OTC listing and ADR Level 1 status. However, the consensus view generally reflects optimism about the company's growth prospects, driven by the increasing demand for biologics CDMO services. Key valuation metrics, such as the P/E ratio, suggest a premium valuation, reflecting expectations of future earnings growth.
What are the main risks for WXXWY?
The main risks for WuXi Biologics (Cayman) Inc. include regulatory changes in China and other markets, increased competition in the CDMO space, reliance on a limited number of large clients, and potential intellectual property disputes. As an OTC-listed company, WXXWY also faces risks related to limited financial disclosure, lower trading volume, and less regulatory oversight.
What are the key factors to evaluate for WXXWY?
WuXi Biologics (Cayman) Inc. (WXXWY) holds an AI score of 49/100 (low). P/E: 25.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does WXXWY data refresh on this page?
WXXWY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven WXXWY's recent stock price performance?
WuXi Biologics (Cayman) Inc. (WXXWY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive end-to-end service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WXXWY overvalued or undervalued right now?
WuXi Biologics (Cayman) Inc. (WXXWY) trades at 25.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WXXWY before investing?
Before investing in WuXi Biologics (Cayman) Inc. (WXXWY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.